Penumbra Inc
corporate_fare Company Profile
Penumbra Inc (NYSE:PEN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for PEN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-02, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 11 rated 8 or above. Recent SEC coverage for PEN spans 10-Q, 8-K, 425, DEFM14A.
Recent high-impact activity:
- Boston Scientific Deal Caps Week as Q3 Revenue Tops Estimates
- Penumbra Tops $410M Revenue, Up 15.6%, But Suspends Guidance on Boston Scientific Deal
- FDA Clears Penumbra's Lightning CAVT for Deep Vein Thrombosis, Opening New Market
- Penumbra Q2 Revenue Beats, but Merger Costs and Tax Normalization Weigh on Earnings
- Penumbra Tops Q2 Revenue, but Merger Costs and Taxes Erode Net Income
Financial Snapshot
Short Interest & Short Volume
5.29 days to coverFINRA reported short interest of 2,403,093 shares in PEN as of the October 30, 2026 settlement, a 6.2% increase from the prior period — about 5.3 days to cover at its recent average daily volume. On November 20, 2026, 45.0% of PEN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.